Clinical Trials Browser

Phase 2 × HER2-positive Gastric Cancer × tislelizumab × Clear all

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer